Supriya Lifescience announced that the five-year consecutive terms for two Independent Directors, Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain, concluded on March 24, 2026. The Board expressed appreciation for their long-term contributions. Following this, the Board reconstituted its standing committees, including the Audit, Nomination and Remuneration, and Stakeholders’ Relationship Committees, effective immediately.
Cessation of Independent Director Tenure
Supriya Lifescience Limited has formally disclosed the conclusion of the tenure for two of its Independent Directors, effective March 24, 2026. This cessation is due to the completion of their statutory term of five (5) consecutive years, as per regulatory requirements. The departing directors are:
- Mr. Dinesh Navnitlal Modi (DIN: 00004556)
- Mr. Dileep Kumar Jain (DIN: 00380311)
The Board conveyed its sincere appreciation for the significant contributions made by both directors throughout their association with the Company.
Board Committee Reconstitution
Subsequent to the change in directorship, the Board of Directors, in its meeting held on February 09, 2026, reconstituted its core committees. The new compositions for the major committees are detailed below:
Audit Committee Composition
| Sr. No. | Director | Role |
|---|---|---|
| 1 | Mr. Hari K. | Chairman |
| 2 | Dr. Ganapati Dadasaheb Yadav | Member |
| 3 | Dr. Satish Waman Wagh | Member |
| 4 | Mr. Manish Panchal | Member |
Nomination and Remuneration Committee Composition
| Sr. No. | Director | Role |
|---|---|---|
| 1 | Mr. Hari K. | Chairman |
| 2 | Dr. Sunil Subhash Bhagwat | Member |
| 3 | Mr. Manish Panchal | Member |
Stakeholders’ Relationship Committee
| Sr. No. | Director | Role |
|---|---|---|
| 1 | Mr. Manish Panchal | Chairman |
| 2 | Dr. Saloni Satish Wagh | Member |
| 3 | Dr. Satish Waman Wagh | Member |
Annexure Details
The associated Annexure A confirms that the reason for the change for both Mr. Modi and Mr. Jain was the completion of the term of five (5) consecutive years of service as Independent Directors, effective at the end of the day on March 24, 2026. The profile and relationship disclosures for both directors were listed as Not Applicable for appointment purposes.
Source: BSE
